Pioneer Select

The Next Level in Custom Bioanalytical Antibody Generation Services

Pioneer™ Select is a custom antibody generation service that delivers high-specificity recombinant antibodies using advanced phage display technology and rapid screening workflows.

Built on a 220‑billion‑sequence library and Bio‑Rad’s proprietary SpyDisplay selection technology, Pioneer Select enables rapid turnaround and flexible engagement models. Each antibody is precisely formatted and labeled via TrailBlazer™ technology to support PK and ADA assays, diagnostic immunoassays, basic research, and QC release testing in Fab, IgG, and additional formats.


Contact a Specialist

What Is Pioneer Select?

Pioneer Select is a platform for custom recombinant antibody generation that uses phage display and high-throughput screening to produce tool antibodies tailored to specific antigen and application requirements.


Why Researchers Choose Pioneer Select

Researchers choose Pioneer Select for its rapid 7‑week delivery, access to a 220‑billion‑sequence phage display library, guided selection strategies, recombinant antibody reproducibility, and flexible antibody formatting options.


Research Needs


How Pioneer Select Helps

Move projects forward faster

Streamlined workflows deliver validated antibodies within 7 weeks

Generate antibodies against challenging targets

The 220-billion-sequence Pioneer library supports a wide range of antigen types

Achieve specific binding characteristics

Guided selection strategies can favour or exclude defined binding behaviours

Support demanding bioanalytical assays

Antibodies can be generated for PK, ADA, in vitro diagnostics, research, and QC applications

Ensure reagent consistency

Recombinant antibody generation provides reproducible, renewable reagents


From Your Antigen to a Bioanalytical Antibody via Premium Phage Display Technology   

     
Icon representing anti-idiotype antibody generation for pharmacokinetic (PK) and anti-drug antibody (ADA) assay development. Icon representing antibody generation against membrane protein targets in their native conformation. Icon representing selection of pH-sensitive antibodies with defined binding and release properties.
Anti-Idiotypic Antibodies
Generating antibodies specific to free
drug, total drug, and drug–target
complexes enables the development
of robust PK and ADA assays.
Anti-Membrane Protein Antibodies
Panning against membrane proteins
in their native conformation using
nanoparticles or overexpression cell
lines is enabled.
pH-Sensitive Antibodies
Screening conditions can be tailored
to selectively identify antibodies with
binding or release properties at defined
pH ranges.
     
Icon representing anti-peptide antibody generation for challenging peptide targets such as GLP-1. Icon representing antibodies designed to bind enzyme active sites for inhibition and functional studies. Icon representing antibodies that selectively recognise protein-protein complexes.
Anti-Peptide Antibodies
Proven success with challenging peptides
(e.g., GLP-1) strengthens our capability
to deliver high-quality anti-peptide
antibodies.
Anti-Enzyme Antibodies
Isolating antibodies that block enzymatic
active sites supports inhibition studies and
structural or functional characterization.
Anti-Protein-Complex Antibodies
Selective isolation of antibodies
recognizing protein–protein complexes
supports mechanistic studies.
     

Pioneer Select Features and Benefits at a Glance


Feature


Benefit

Pioneer library and SpyDisplay technology

Enables high-affinity antibody selection to support demanding assays. Guided selection enables desired cross-reactivity while avoiding undesirable ones

Diverse antigen compatibility

Supports targets including but not limited to recombinant proteins, antibodies, cells, haptens, peptides, oligonucleotides, toxins, and inactivated viral or bacterial targets.

Streamlined and automated workflow

Delivers validated antibodies within just 7 weeks, minimizing re-work, accelerating timelines, and keeping your project reliably on schedule

Flexible engagement

Provides research use, optional therapeutic licensing, and deployment across in vitro diagnostics* and clinical monitoring applications

*An agreement or indemnity letter may be required in some cases.


Panning for Your Exact Requirements

Pioneer Select employs tailored panning strategies that steer the selection toward your exact binding requirements.

Selective Binding — No Cross-Reactivity

Illustration representing antibody selection for specific target binding while avoiding cross-reactivity to related antigens. Requirement: Antibodies binding the antigen but not a closely related antigen (CRA).

Strategy: Selection on antigen with library subtraction using the CRA to deplete unwanted cross-reactive binders.

Multi-Species or Multi-Antigen Binding

Illustration representing selection of antibodies that recognise multiple related antigens across species. Requirement: Antibodies recognizing epitopes present on two or three antigens (e.g., human and mouse target).

Strategy: Alternating selection rounds on two or three closely related antigens during panning.

Non-Competing Epitope Selection

Illustration representing identification of antibodies binding distinct non-overlapping epitopes. Requirement: Two antibodies binding distinct, non-overlapping epitopes for sandwich assay formats.

Strategy: Epitope binning to identify binders to distinctive epitopes.

Performance under Assay Conditions

Illustration representing antibody selection under defined assay conditions to identify functionally compatible binders. Requirement: Antibodies suitable under specific conditions, e.g., organic solvents or matrix components.

Strategy: Performing antibody selection directly under the target assay conditions to select functionally compatible binders.


Fit-for-Purpose Antibodies for Your Critical Assays

Pharmacokinetic (PK) Assay
Antibodies specific for free drug, total drug, and drug–target complexes empower assay teams with unmatched design freedom, delivering exceptional sensitivity and reliability.
Anti-Drug Antibody (ADA) Detection
Selective anti‑idiotype antibodies support dependable detection of treatment‑induced immune responses throughout clinical immunogenicity investigations.
Diagnostic Immunoassay
Characterized antibody tools function as detection reagents, surrogate sera, or fully human reference materials, facilitating accurate performance across diverse in vitro diagnostics.
Quality Control (QC) Release Assays
Consistent, performance‑verified antibody reagents ensure batch integrity, and protect product quality throughout biopharmaceutical and vaccine production.

Frequently Asked Questions

What is Pioneer Select?


Pioneer Select is a Bio-Rad custom bioanalytical antibody generation service that uses the pooled Pioneer phage display library in a streamlined panning strategy. It is specifically designed to deliver high‑affinity, assay‑ready antibodies for PK, ADA, research, clinical monitoring, and IVD applications.

How quickly will I receive my antibodies?


Pioneer Select projects are completed within 7 weeks, providing validated antibodies prepared for subsequent applications. However, you should anticipate approximately 3 weeks of lead time.

Can I use Pioneer Select for biotherapeutic antibody discovery program?


We have the Pioneer Antibody Discovery Platform, specifically designed for discovering developable, diverse, and high-affinity biotherapeutic antibody candidates against challenging targets. 


Contact a Specialist


Contact Us

Address  Phone  Email

Campus Neuried, Anna-Sigmund-Str. 5
82061 Neuried, Germany  

+49 89 809095-10

pioneer_services@bio-rad.com